Incendia Therapeutics is a biotechnology startup founded in 2019 in the United States. The company is dedicated to discovering and developing novel anti-cancer medicines that are specifically designed to reprogram the tumor microenvironment. Their lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that aims to punch holes in the extracellular matrix barrier created by the tumor, thereby allowing immune cells to infiltrate and attack the tumor. This program is on the cusp of entering Phase 1 clinical trials. Following PRTH-101, Incendia Therapeutics has a pipeline of preclinical projects targeting other components of the tumor microenvironment that promote immune exclusion. The company utilizes a precision oncology approach and proprietary AI technology to digitally deconstruct the tumor microenvironment and develop insights to enable biomarker-driven patient selection strategies for clinical applications. Their recent milestone includes a significant $65.00M Series A investment received on 03 November 2021 from a consortium of notable investors, including Breakout Ventures, KdT Ventures, Alexandria Venture Investments, Northpond Ventures, Park West Asset Management, Section 32, Taiho Ventures, Tekla Capital, Pfizer Venture Investments, and Creacion Ventures. This strong financial backing positions Incendia Therapeutics for further advancements in their mission to overhaul cancer treatment by reprogramming the tumor microenvironment.
There is no investment information
No recent news or press coverage available for Incendia Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
